These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 47697)

  • 1. Complement system studies in systemic lupus erythematosus (SLE).
    Teisberg P
    Acta Med Scand; 1975; 197(1-2):131-4. PubMed ID: 47697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermal-epidermal deposition of complement components and properdin in systemic lupus erythematosus.
    Jordon RE; Schroeter AL; Winkelmann RK
    Br J Dermatol; 1975 Mar; 92(3):263-71. PubMed ID: 1096924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.
    McLean RH; Michael AF
    J Clin Invest; 1973 Mar; 52(3):634-44. PubMed ID: 4630981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients.
    Schroeter AL; Conn DL; Jordon RE
    Ann Rheum Dis; 1976 Aug; 35(4):321-6. PubMed ID: 970989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus.
    Schrager MA; Rothfield NF
    J Clin Invest; 1976 Jan; 57(1):212-21. PubMed ID: 1245600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level.
    Perrin LH; Lambert PH; Nydegger UE; Miescher PA
    Clin Immunol Immunopathol; 1973 Nov; 2(1):16-27. PubMed ID: 4204416
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunopathological changes during immunosuppressive treatment of glomerulonephritis in systemic lupus erythematosus.
    Munthe E; Brodwall EK; Oyri A; Natvig JB
    Acta Med Scand; 1974 Oct; 196(4):291-9. PubMed ID: 4139879
    [No Abstract]   [Full Text] [Related]  

  • 9. Measurement of complement components in systemic lupus erythematosus by radial immunodiffusion.
    Finberg R; Barland P; Grayzel AI
    Am J Clin Pathol; 1977 Jan; 67(1):97-9. PubMed ID: 401557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.
    Hunsicker LG; Ruddy S; Carpenter CB; Schur PH; Merrill JP; Müller-Eberhard HJ; Austen KF
    N Engl J Med; 1972 Oct; 287(17):835-40. PubMed ID: 4627271
    [No Abstract]   [Full Text] [Related]  

  • 11. Glomerular and dermal deposition of properdin in systemic lupus erythematosus.
    Rothfield N; Ross HA; Minta JO; Lepow IH
    N Engl J Med; 1972 Oct; 287(14):681-5. PubMed ID: 4115613
    [No Abstract]   [Full Text] [Related]  

  • 12. Family study of systemic lupus erythematosus: analysis of the clinical history, skin immunofluorescence, and serologic parameters.
    Lowenstein MB; Rothfield NF
    Arthritis Rheum; 1977; 20(7):1293-1303. PubMed ID: 334183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM; Wilson MR; Tan EM
    J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid.
    Provost TT; Tomasi TB
    J Clin Invest; 1973 Jul; 52(7):1779-87. PubMed ID: 4352464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposits of immunoglobulins and complement C3 in clinically normal skin of patients with lupus erythematosus.
    Ullman S; Halberg P; Wolf-Jürgensen P
    Acta Derm Venereol; 1975; 55(2):109-12. PubMed ID: 48312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways of complement activation in chronic discoid lupus: serologic and immunofluorescence studies.
    Schrager MA; Rothfield NF
    Arthritis Rheum; 1977 Mar; 20(2):637-45. PubMed ID: 322668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunoserological follow-up and clinical finding in SLE].
    Naganawa C; Kojima I; Ozawa A
    Rinsho Byori; 1971 Aug; 19():Suppl:478. PubMed ID: 5316596
    [No Abstract]   [Full Text] [Related]  

  • 18. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon production by lymphocytes from patients with systemic lupus erythematosus.
    Alarcón-Segovia D; Ruiz-Gómez J; Fishbein E; Bustamante ME
    Arthritis Rheum; 1974; 17(5):590-2. PubMed ID: 4370121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.